Targeting signal transduction in the discovery of antiproliferative drugs  by Saltiel, Alan R. & Sawyer, Tomi K.
Minireview 887 
Targeting signal transduction in the discovery of 
antiproliferative drugs 
Alan R Saltiei and Tomi K Sawyer 
Derangements in the signal transduction pathways 
controlling cell growth can lead to cancer. Two areas 
of growth factor signaling offer novel opportunities for 
therapeutic intervention: protein-protein interactions 
and phosphorylation cascades. 
Address: Parke-Davis Pharmaceutical Research, Warner-Lambert 
Company, 2800 Plymouth Road, Ann Arbor, MI 48105, USA. 
Chemistry & Biology November 1996,3:687-893 
Q Current Biology Ltd ISSN 1074-5521 
In the past .few years, enormous progress has been made 
in elucidating the cellular events mediating the actions of 
hormones and growth factors. New intracellular pathways 
of signal transduction are being discovered at an extraordi- 
nary rate, revealing the complicated networks that under- 
lie the hormonal regulation of metabolism, proliferation 
and differentiation of cells. Occasionally, these regulatory 
networks cease to function properly, and the subsequent 
disregulation of signaling pathways can result in disease. 
Many endocrine and immunological disorders arise from 
aberrant signal transduction. The most profound effect of 
the advances in our understanding of signal transduction 
will undoubtedly be in the area of understanding and 
treating proliferative diseases, such as cancer. 
The intracellular pathways regulating cell growth in 
reponse to external signals all involve protein phosphory- 
lation. This protein modification is widely used in cell 
regulation, and usually produces a conformational change 
that may modify the activity of a protein or its interaction 
with other molecules. The universal role of protein phos- 
phorylation is seen most prominently in the case of the 
protein products of proto-oncogenes, the normal cellular 
counterparts of the o&genes that are responsible for 
much or all of human cancer. A growth signal may be 
delivered to the nucleus either via a pathway triggered 
by a variety of extracellular stimuli or by the expression 
of intracellular oncogenes. The pathways used share 
many elements but each has some distinct features. This 
has led to the concept that combinatorial diversity of 
signaling proteins is used to ensure specificity in signal 
initiation, Upon activation, many growth factor receptors 
can specifically interact with different intracellular signal- 
ing proteins, often through distinct protein-interaction 
motifs in these proteins, typified by Src homology 2 
@HZ) domains. These protein-protein interactions repre- 
sent the first level of specificity in signal transduction. 
The next step is the activation of different signaling 
cascades, including those involving phospholipid metab- 
olism, calcium mobilization, ion channels and protein 
kinases and phosphatases. Notable among these is the 
Ras-mitogen-activated protein (MAP) kinase pathway, a 
major route of signal transduction to the nucleus. 
Many of the proteins involved in growth factor signaling 
were first identified as the products of oncogenes in 
human or animal tumors. Signal transduction pathways are 
currently some of the most attractive targets for therapeu- 
tic intervention in proliferative diseases. But, because of 
our lack of experience with pharmacological agents that 
target intracellular signaling, it is difticult to predict results 
of the selective blockade of a single pathway. Experiments 
in tissue culture cells suggest that many signaling media- 
tors are universally utilized by growth factors, cytokincs, 
hormones, neurotransmitters, biogenic amines and other 
extracellular stimuli. On the other hand, it may be mis- 
leading to extrapolate from studies &J vitro to the physio- 
logical setting, since some of these agents do riot cause 
growth in a&o, and the pathways may have taken 011 exag- 
gerated importance in immortalized cell lines. Moreover, 
signaling pathways involved in growth control tend to be 
redundant in tissue culture cells, so that the failure of a 
single pathway may be compensatecl for by the activity of 
another. Thus, the selection of targets for drug discovery in 
proliferative diseases is tess than straightforward. And even 
when the target is selected, difficulties remain. Is it po&i- 
bie to attain the specificity necessary for ancitumor agents 
to be useful without inhibiting normal cell proliferation? 
Will signal transduction inhibitors merely stop the tumor 
from growing further, or will they change the behaviour of 
the tumor cell causing it to die or differentiate? 
There is a raging debate about the ultimate usefulness of 
targeting signal transduction in human disease, which will 
probably be resolved only after the discovery of potent 
inhibitors of these pathways. An ideal therapeutic agent 
for proliferative diseases will have good oral bioavailability 
and cell permeability, a long half-life and specificity for its 
target tissue. These requirements indicate that non- 
peptide molecules that inhibit the function or the expres- 
sion of an aberrant protein are likely to be most effective. 
The diversity of signaling pathways suggests many new 
targets for intervention. A great deal of attention has 
focused on growth factor receptors, particularly their tyro- 
sine kinase activity [l]. Others have chosen as targets the 
ultimate effecters in signal transduction, the transcription 
factors responsible for regulating, cell-cycle entry [Z], or 
the cyclin-dependent kinases that regulate progression 
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Model of pTyr-Glu-Glu-lie binding to the Src 
SH2 domain. The intermolecular binding 
interactions of pTyr-Glu-Gtu-lie with the Src 
SH2 domain are depicted as suggested from 
an X-ray crystallographic structure [71. The 
binding pockets for the pTyr and P+3 
Ile sidechains, as well as possible hydrogen- 
bonding interactions between the 
phosphopeptide, SH2 protein and several 
structural waters, are indicated. 
through the cell cycle 133. In this review we focus on two 
areas in growth factor signaling thar: represent opportuni- 
ties for therapeutic intervention: SH2 domains, as a para- 
digm for protein-protein interactions, and the MAP kinase 
pathway, as an example of phosphorylation cascades. 
Src homology domains 
The discovery of the noncata!ytk :e&tory regions 
referred to as SK homology (SH) domains has been critical 
in ‘deconvoluting’ interactions between enzymes and their 
substrates and regulatory proteins and their targets, for a 
number of signal transduction pathways [4]. SH2 domains 
bind specific phosphotyrosinc (pTyr)-containing proteins, 
depending on the sequence of rhe amino acids on the 
carboxy-terminal side of the pTyr residue. For example, 
the Src SHZ domain prefers the sequence pTyr-Glu-Glu- 
Ile, and the adaptor molecule Grb2 prefers pTyr-Tyr- 
Asn-Tyr [S]. The SH3 domains, on the other hand, specifi- 
cally bind proline-rich sequences of cognate proteins. 
Because of the pseudosymmetrical nature of the SHJ 
domains, target sequences may be bound either in the 
N+C direction or the C+N direction [6]. 
X-ray structures of the ligand-bound Src SHZ domain 
[7] have been used to design the first peptidomimetic 
antagonists of Src signaling [S]. A molecular map of the 
tetrapeptide sequence pTyr-Glu-Glu-Ile complexed 
with Src SH2 domain 171 shows the pTyr-binding pocket 
and a second binding site for the ‘P+3’ ILe residue (Fig. 1). 
Peptide scaffold-based approaches attempting to replace 
the internal dipeptide, Glu-Glu, with either flexible or 
rigid linkers [9], have thus far failed to yield potent 
analogs. However, peptidomimetics have been successfuliy 
designed in which stereoinversion at the second residue 
(P+Z) to the n-configuration, and sidechain substitution 
to hydrophobic functionalities (e.g. cyclohexyl or naph- 
thyl), allows the P+3 Ite sidechain to access its hydropho- 
bic binding pocket [10,X1]. Indeed, these compounds 
showed binding affinities essentially identical to those 
of the longer phosphopeptides containing the pTyr-Glu- 
Glu-Ilc sequence ([l-3], Fig. 2). Recently, a series of 
potent peptidqmimet-its with novel carboxy-terminal func- 
tionalizarion (e.g. with a ‘transposed’ sidechain of the P+l 
Glu or with a conformational constraint introduced by 
using a pyrrolidine ring; see Fig. 2, compounds 6-8) have 
been designed based on the structural information [7] and 
synthesized. Stud& focused on the pTyr residue of 
peptide antagonists of the SK St-12 domain [9] have shown 
chat the phosphate ester is particularly critical for molecular 
recognition, and that significant loss in binding occurs 
when it is replaced with sulfacc, carboxylate, nitro, hydroxy 
or amino groups. Substitution of the pTyr residue by diffu- 
oromethylphosphonate-(FZPmp)-modified analogs is now 
known co give more stable derivatives ([&IO], Fig. Z), 
providing another step towards cellutarly active ‘second 
generation’ compounds. 
Recently, high resolution three-dimensional structures for 
the noncatalytic adaptor protein GrbZ (the apoprotein and 
its individual SHZ and SH3 domains) have been described 
[l&13]. An X-ray structure of a phosphopeptide complex 
provided insight into why GrbZ SH2 prefers to bind 
pTyr-Xxx-Asn-Yyy sequences. The binding interactions 
of Lys-Pro-Phe-p’ljir-Val-Asn-Val showed that chc phos- 
phopeptide adopts a p-turn conformationabout the P-P+3 
residues (Fig. 3), and that the P+2 Asn sidechain caxbox- 
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Figure 2 
Discovery of peptidomimetic antagonists of 
the Src SH2 domain. The structure-based 
design of peptidomimetic antagonists of the 
Src SH2 domain is shown relative to the 
pTyr-Glu-Glu-lie parent sequence. Key 
prototype leads include compounds t [lOI 
and 2 11 11. Several ‘second generation’ 
compounds are also indicated, including 
F,Pmp-modified analogs [Sl. 
1 
amide moiety is extensively hydrogen-bonded to the 
protein. In contrast to the well-defined binding pocket for 
the P+3 Ile in the Src SHZ ligand, the P-t3 Val engages in 
limited surface hydrophobic interactions with Grh2 SH2, 
because the TrplZi residue of Grb2 3H2 sterically blocks 
the binding pocket. 
The Ras-MAP kinase pathway in growth factor signaling 
-Although there was general agreement among investiga- 
tors in the early 1980s that protein tyrosine kinases are 
important in growth control, tyrosine phosphorylations 
were relatively scarce compared to those found on serine 
and threonine residues in cells treated with growrh factors 
or transfected with tyrosine kinase oncogenes. Many inves- 
tigators therefore suspected that serine kinases were acti- 
vated directly or indirectly after tyrosine phosphorylation 
by growth factor receptors, dramatically amplifying the 
initial signal in the cell. Although no direct connection 
between tyrosine and serine protein kinases was found, 
genetic studies in the yeast Su~&rnn~yces cermislue, the flv 
LL-~~o@ilti me&ogaster and the nematode Catmrhuhiitis 
eleg:ans revealed that the GTP-binding proteins thar are 
mcmbecs of the Ras family are important in regulation 
1141. Ras proteins in these organisms are regulated by func- 
tional homologs of mammalian tyroaine kinase systems, 
suggesting that Ras might mediate the effects of tyrosine 
kinases on serine kinase activation. 
We now know that Ras does indeed provide a link 
between growth factor receptors and serine kjnases. In a 
sense, Ras functions as an amplifying ‘switch’ that converts 
the signals from tyrosine kinases into a language decipher- 
able by serine kinases. In general, tyrosine kinases signal 
Ras to the ‘on’ state by promoting its binding to GTP, via 
the activity of a protein named for its firczs@ila homofog, 
Son of sevenless (SOS). The subsequent hydrolysis of 
GTP to GDP is stimulated by a GTPase-activating 
protein, or GAP, turning Ras off. Ras proteins are mutated 
in human cancers. In fact, 1 So % of human tumors contain 
activating ras gene mutations. Our current understanding 
of Ras regulation suggests a number of therapeutic targets, 
both upstream and downstream of the protein. The 
domains that mediate the interactions of Kas with its 
inhibitor, GAP, and its activator, SOS, have been localized. 
Peptides modeled from these regions block these interac- 
tions and inhibit Ras function when microinjected into 
cells. Potent, nonpeptidic inhibitors of these interactions 
have not yet been developed. 
Since many of the oncogenic mutations found in rQs 
maintain the protein in the GTP-bound configuration, 
efforts have focused primarily on inhibiting the already 
activated forms of the protein. One approach is to block 
the post-translational attachment of isoprenoid (or prcnyl) 
lipids to the protein,. required for Ras to localize at the 
plasma membrane [lS]. This prenylation reaction involves 
thioether linkages of either farnesyl or the longer geranyl- 
geranyl groups to sequences near the carboxyl terminus 
of the protein. The enzymes that catalyze these lipid 
attachments, called prenyltransferases, recognize a specific 
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Model of pTyr-Val-Asn-Val binding to the 
Grbl SH2 domain. The intermolecular binding 
interactions of pTyr-Val-Asn-Val with the 
GrbZ SHP domain are depicted as suggested 
from an X-ray crystallographic structure 1131. 
The binding pockets for the pTyr and the P+i 
Val as well as possible hydrogen-bonding 
between phosphopepfide and SH2 protein as 
well as intramolecular hydrogen-bonding of 
the phosphopeptide are indicated. 
tetrapeptide motif in the Ras protein, called a ‘CAAX’ 
box, in which C represents cysteine, the two A’s are 
aliphatic amino acids, and X is a mcthionine, serinc or 
leucine residue. Both substrace-based and non-Cys- 
containing peptide inhibitors [l&18] have been explored. 
Relative to peptide-substrate structure-based design 
efforts, peptidomimetics incorporating Psi-[CH2NH]-sub- 
stitutions [16] or a benzodiazepine replacement of’ the 
central dipeptide moiety [17] have yielded high affinity 
inhibitors. In another series of inhibitors, the central 
dipeptide is replaced with various isomcric and/or substi- 
tuted derivatives of amino-benzoic acid [i9], including the 
biphenyl derivative which is particularly effective [ZO]. 
Thus, peptide scaffolds that are conformationally flexible 
or constrained as well as nonpeptide template replace- 
ments can be used to link the Cys and Met substructures. 
Although some of these compounds have free sulfhydryl 
groups, there is no evidence that they become farnesy- 
lated, suggesting that the substitured peptide inhibitors 
may bind the target enzyme in the same way as their 
peptide substrate counterparts, Although preliminary 
results look promising, it is unclear whether the modifica- 
rion of other prenylated proteins will also be affected. 
Moreover, since normal Ras also requires prenylation for 
activation, inhibition of prenylation should also block 
norma Ras functions. 
The complexity of the activation of Ras by tyrosine kinases 
pales in comparison to its downstream pathway. Again, 
much of what we have learned about the downstream 
signals has emerged from studies on yeast, flies and worms 
[14]. Upon its activation, GTP-bound Ras recruits protein 
serine kinases to the membrane, where they can be acti- 
vated. The best characterized of these interactions involves 
the pmto-oncogenic serine kinase Raf [Zl]. Although the 
mechanism by which Raf is activated remains unknown, its 
recruitment by Ras to the plasma membrane is essential. 
Once ,activated, Raf can in turn phosphorylate another 
protein kinase, called MEK or MAP kinase kinase. MEK 
exhi birs sequence homology to the $rl and ste7 gene prod- 
ucts of Sc/z~~osracc~~~o~y~e.~ pomOe and S. cer-evisZu~ [ZZ]. This 
enzyme, which represents a site of integration from other 
signaling pathways, is a dual specificity kinase that phos- 
phorylates MAP kinase on both tyrosine and threonine 
residues, resulting in its activation. Upon activation, MAP 
kinase [Z3] can translocate into the nucleus, where it cat- 
alyzes the phasphorylation of transcription factors such as 
~62~“~, initiating a transcriptional program that leads the 
cell to commit co proliferation or differentiation (Pig. 4). 
MAP kinase can also phosphorylate a number of other pro- 
teins involved in ceIluIar signaling, including other kinases 
and phospholipases. 
At first glance, this phosphorytation cascade, known as the 
MAP kinase pathway, appears to be a linear trail connecting 
Ras to the nucleus. In reality, however, the circuitry is quite 
coniplex, and this pathway interacts extensively with ocher 
phosphor$Iarion cascades that are used in a diverse set 
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Figure 4 
Regulation of the MAP kinase pathway by 
growth factors. A scheme is depicted for the 
molecular interactions involved in the 
activation of MAP kinase. MEK (MAP kinase 
kinase) is activaled by Raf once Raf has been 
recruited to the plasma membrance by 
activated Ras. MEK phosphorylates MAP 
kinase, activating it and allowing it in turn to 
phosphorylate a number of downstream 
targets such as: ppQO’% p62TcF, which leads 
to commitment to differentiation or 
proliferation; pkospholipase A, (PLA2) or 
PHAS-1; PKA, protein kinase A, PKC, protein 
kinase C, SYP. 
of responses to extracellular stimuli, ranging from mating 
responses in yeast to stress and mitogenic responses in 
higher eukaryotes. These complex pathways offer numer- 
ous opportunities for integration of diverse stimuli into a 
single response, yet also allow for the specificity, feedback 
and crosstalk that are the hallmarks of signal transduction. 
MAP kinase itself absolutely requires both threonine and 
tyrosine phosphorylation for activation, making it one of the 
most tightly regulated enzymes in the signaling process. It 
can be activated only by MEK, but can be inactivated by 
serine phosphatases, tyrosine phosphatases, and a dual 
specificity phosphatase called MKPF, or MAP kinase phos- 
phatase [‘24]. MEK is one of the unusual enzymes in the 
signaling pathway. This dual specificity kinase exhibits 
astonishing substrate specificity for a protein kinase, phos- 
phorylating only members of the MAP kinase family. MEK 
itself is activated by phosphorylation on serine residues. 
Although Raf is the best characterized of the MEK kinases, 
there are others that may serve to integrate growth signals 
from different stimuli [25]. 
A number of sites in the MAP kinase pathway are 
amenable to therapeutic intervention. Agents that inhibit 
these enzymes might be especially useful in targeting 
tumors that contain activating Ras mutations, since i%is is 
directly upstream of these enzymes and they are essential 
for the propagation of the Kas pathway. One example 
of a compound that affects the MAP kinase pathway is 
PIN8059 (Fig. 5). This is a kinase inhibitor which is 
non-competetitive for ATP and blocks MEK activity 
and the subsequent stimulation of MAP kinase without 
inhibiting any other protein or lipid kinases [26]. The 
precise mechanism by which this compound blocks MEK 
activity is srill unknown, but it appears to be an allosteric 
regulator of MEK, preventing its phosphorylation and 
subsequent activation through a novel regulatory site on 
the enzyme [27]. 
PI398059 blocks growth-factor-dependent activation of 
MAY kinase, inhibits DNA synthesis in a variety of cell 
types and prevents ncurocrophin-induced differentiation 
of PC-12 cells. It can revert Ras-transformed fibroblasts to 
a normal phenotype, suggesting rhac blockade of this 
pathway might be useful in preventing the progression of 
tumorigenesis I%]. In contrast to the effects of the MEK 
inhibitor on growth, it has no effect on metabolism, for 
example the regulation of carbohydrate and lipid metabo- 
lism by insulin [28]. As insulin signals through a tyrosine 
kinase receptor, it is clear that, although many hormones 
can activate the MAP kinase pathway, it is not always used 
for transduction of the relevant signal. 
In addition ro its antiproliferative effects [X5], FD98059 
also prevents the MAP kinasc-mediated phosphorylation of 
other cytoplasmic substrates in some cells, including other 
protein kinases, phospholipase A,, and even the upstream 
signaling proteins known to be targets of desensitization. 
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Structure of PD98059. an inhibitor of MEK. 
For example, PD98059 blocked the growth-factor-induced 
phosphorylation of SOS, causing it to uncouple from Grb2, 
reducing the further activation of Ras 1291. Thus, in normal 
cells, the activation of the MAP kinase pathway leads to 
a desensitizing retrophosphorylation that prevents the per- 
sistent activation of the Ras protein, perhaps explaining in 
pact why growth factor activation does not generally lead 
to tumors. 
There may also be a second way in which the conse- 
quences of MAP kinase pathway activation are controIled. 
In the case of neuronal differentiation, the kinetics of 
MAP kinase activation appear important in determining 
whether a cell commits co differentiate. In general, pra- 
longed activation and nuclear translocation of MAP kinase 
is associated with neurite outgrowth in PC-12 cells; mito- 
geoic stimuli chat activate MAP kioase transiently do not 
produce neuronal differentiation. Similarly, when 3T3 
cells are engineered to respond to NGF by causing them 
to express the t&A NGF receptor they show growth arrest 
and differentiation in the presence of NGE These 
responses are associated with induction of the cyclin- 
dependent kinase inhibitor p21cip1~~f1, and the subse- 
quent down-regulation of CDK4 activity (K Pumiglia and 
SJ Decker, personal communication). The effect can be 
blocked with PD98059, suggesting that it is the sustained 
acrivacion of MAP kinase induced by NGF that is respon- 
sible for the dramatic change in the phenotype of the cell. 
Presumably MAP kinase acts via the phosphorylarion of’ 
proteins, perhaps the products of immediate early genes. 
Development of signal transduction inhibitors 
Signal transduction is a particularly attractive target for 
research aimed at discovering antiproliferative agents 
because it is the site of the fundamental lesion leading to 
uncontrolled cell growth. Such agents should be highly spe- 
cific, avoiding the toxicities associated with standard cyto- 
toxic agents, which, in general, kill proliferating cells 
without distinguishing between normal and pathological 
growth. Thus, specificity must be constantly monitored 
throughout development. Tmditionally, agents progress 
along a developmental path that increases iri complexity, 
cost and potential pitfalls over time. It may be possible to 
streamline much of this process when developing inhibitors 
of signal transduction. All of the pathways described above 
involve fairly well-characttirized proteins for which the 
genes have been cloned. These proteins have already been 
the focus of a great deal of structural and functional analysis, 
and can usually be expressed in large quantity. They are 
therefore amenable to in z&-u biochemical assays &a ratio- 
nal, structure-based design, or random screening of libraries 
of low molecular weight peptidomimetics or other organic 
molecules. Agents active in such screens can be evaluated 
in counter-screens devised to detect undesirable activity. 
For example, inhibitors of the GrbZ SHZ domain would be 
counter screened with a series of irrelevant SH2 domains, to 
evaluate the specificity of the interaction. 
Active and highly specific compounds that emerge from 
biochemical assays are usually evaluated further in cellular 
assays in tissue culture cells. For example, a MEK 
inhibitor can be evaluated for its ability to prevent the 
growth-factor-dependent activation of MAP kinase in 
fibroblasts. Such an assay will revea1 whether a compound 
can traverse the cell membrane, and will confirm its effi- 
cacy and specificity. Once a compound chat specifically 
blocks a pathway has been found, it is possible to test how 
important that pathway is in cell proliferation. Initial eval- 
uations are likely to be carried out in a well-established 
model system, such as a mouse fibroblast cell line, fol- 
lowed by a panel of human tumor cells. Such ‘tertiary’ 
assays may include DNA synthesis, cell proliferation, cell 
survival, colony formation, cell-cycle progression or moni- 
toring of morphological markers in cells treated with 
growth factors or cransfor,rrrked with viral oncogenes. 
Although cellular assays are unlikely co be good predictors 
of clinical efficacy for antiproliferative agents, it may be 
possible to resolve a number of issues regarding the biology 
of a tumor type at this level of investigation. Indeed, there 
are far more questions than answers, since results are not 
yet available from experiments exposing tumors to signal 
transduction inhibitors. Will transformed cells develop 
resistance to such agents? Will signal transduction inhibitors 
synergize with or sensitize tumors to traditional cycotoxic 
drugs? Will the blockade of growth factor/oncogene signal- 
ing induce cells to undergo apoptosis or differentiation? 
WiIl the blockade of growth factor signaling pathways lead 
to clinically unacceptable side effects? 
Since, signal transduction is a novel and untested target for 
the discovery of antiproliferative drugs, signal transduction 
inhibitors will require nontraditional approaches to devel- 
opment. The clinical efficacy and toxicity of such com- 
pounds remain complerely unexplored and are difficult to 
predict for these compounds, like all chemotherapeutic 
agents. It is possible, even likely, that the successful use of 
such mechanism-based therapies will be highly individual- 
ized, perhaps dependent not only on tumor cell type, but 
also on specific determinants of the molecular lesions 
Minireview Signal ttansduction as a drug target Salt&l and Sawyer 893 
present in a given patienr’s cancer. As for all aspects of 
drug development, there are many hurdles and uncertain- 
ties to overcome. Nevertheless, the fact that cancer is now 
known to result from derangements in the signal cransduc- 
tion pathways controlling cell growth means that we are 
now able to focus the attack where the problem arises. 
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